mBIOTA Labs Receive Extensive Recognition at 2025 American College of Gastroenterology Annual Meeting

Audio By Carbonatix

SANTA MONICA, Calif.--(BUSINESS WIRE)--Nov 5, 2025--

mBIOTA Labs, an emerging medical food company revolutionizing medical nutrition for the management of gastrointestinal (GI) conditions, announced that four clinical studies leveraging mBIOTA Elemental™ Diet and two studies using mBIOTA Labs’ 2025 national gut health survey were presented at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting in Phoenix, Arizona.

The abstracts, presented by Dr. Ali Rezaie and a team of renowned researchers at Cedars-Sinai Medical Center in collaboration with mBIOTA Labs, assessed the prevalence of gastrointestinal symptoms among U.S. adults and the effectiveness of potential applications of mBIOTA Elemental, the first palatable elemental diet. One abstract, titled “Novel Strategy for Deep Remission in EoE: Combining Dupilumab With Palatable Elemental Diet,” was awarded the prestigious Presidential Poster Award at ACG 2025.

The poster presentations featuring mBIOTA Elemental Diet and mBIOTA Labs’ 2025 national gut health survey include:

“Novel Strategy for Deep Remission in EoE: Combining Dupilumab With Palatable Elemental Diet”

Presidential Poster Award winner

• This case explored the utilization of a palatable elemental diet for the management of intestinal methanogen overgrowth (IMO) in a 41-year-old man with active Eosinophilic esophagitis (EoE).
• The findings underscore the potential of elemental diets to induce deep remission in patients with incomplete response to dupilumab, a common EoE treatment.

“Visceral Fat Reduction via Palatable Elemental Diet Is Linked to Microbial and Hormonal Shifts in Adults”

• Clinical study findings reveal that changes in the gut microbiome, modulated by a palatable elemental diet (mBIOTA), are associated with sustained visceral and body fat loss and elevated systemic levels of GLP-1 and leptin after reintroduction of a regular diet.

“Outpatient Management of Partial Small Bowel Obstruction Using an Oral Palatable Elemental Diet”

• This study explored managing partial small bowel obstruction (pSBO), often occurring due to post-surgical adhesions, as an outpatient with a palatable elemental diet (mBIOTA).
• This case highlights that outpatient management of pSBO without alarm features is feasible with the use of an exclusive oral palatable elemental diet.

“Prevalence, Duration, and Healthcare-Utilization Behavior Among US Adults With Chronic Gastrointestinal Symptoms: A Nationally Representative Survey”

• National survey findings uncovered that while chronic GI symptoms affect the majority of U.S. adults, medical care is often underutilized even among those with long-standing symptoms.
• These findings highlight the urgent need for targeted public health messaging and improved clinician-patient communication around functional GI disorders.

“Elemental Diets Do Not Induce Fungal Overgrowth in Vitro and Reduce Fecal Candida albicans in Humans”

• This clinical study demonstrated that elemental diets and their macronutrient components do not promote fungal overgrowth in vitro and may reduce Candida burden in vivo.

“Prevalence and Perception of Post-Prandial Bloating in the U.S. Adult Population: Results From a Nationally Representative Survey”

• National survey findings reveal that bloating affects more than 20% of the population, but it is normalized or ignored in more than half of those affected.

“The clinical evidence demonstrated in these abstracts and the overall recognition of expanded use cases for mBIOTA Elemental Diet reinforce our dedication to improving overall GI health management with effective, patient-centered solutions,” said Nicola Wodlinger, CEO of mBIOTA Labs. “mBIOTA Labs has significantly improved the quality of life for patients living with small intestinal bacterial overgrowth, and we look forward to continuing to expand the applications of mBIOTA Elemental for wider patient groups.”

mBIOTA Labs’ palatable elemental diet offers patients an approachable and clinically reliable option to manage GI conditions like small intestinal bacterial overgrowth (SIBO) and IMO. For more information on mBIOTA Labs, mBIOTA Elemental, and related clinical findings, visit www.mBIOTA.com.

About mBIOTA Labs

mBIOTA Labs empowers individuals with evidence-based nutrition solutions that enhance quality of life. Trusted by the medical community, mBIOTA Labs harnesses proprietary Amino Taste Modification Technology (ATMT) to create science-backed medical foods designed to support individuals with a wide range of digestive issues. mBIOTA's award-winning, clinically proven, palatable elemental diet, mBIOTA Elemental™, revolutionizes medical nutrition for the dietary management of GI dysfunction, including small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD) such as Crohn’s disease and colitis, eosinophilic esophagitis (EoE), and other conditions. mBIOTA is actively investigating and researching expanded applications of the elemental diet to aid and provide solutions to more patients. Learn more about mBIOTA Labs and published research supporting mBIOTA Elemental Diet by visiting www.mBIOTA.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251105490374/en/

CONTACT: For mBIOTA Labs:

Matter Communications

[email protected]

KEYWORD: CALIFORNIA ARIZONA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: VITAMINS/SUPPLEMENTS FITNESS & NUTRITION HEALTH CLINICAL TRIALS

SOURCE: mBIOTA Labs

Copyright Business Wire 2025.

PUB: 11/05/2025 11:18 AM/DISC: 11/05/2025 11:18 AM

http://www.businesswire.com/news/home/20251105490374/en